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Abstract
Background: Although electroconvulsive therapy (ECT) is regarded as one of the efficient treatments for intractable
psychiatric disorders, the mechanism of therapeutic action remains unclear. Recently, many studies indicate that
ECT affects the immune-related cells, such as microglia, astrocytes, and lymphocytes. Moreover, microglial activation
and astrocytic activation have been implicated in the postmortem brains of schizophrenia patients. We previously
demonstrated that Gunn rats showed schizophrenia-like behavior and microglial activation in their brains. The
present study examined the effects of electroconvulsive shock (ECS), an animal counterpart of ECT, on
schizophrenia-like behavior, microgliosis, and astrogliosis in the brain of Gunn rats.
Methods: The rats were divided into four groups, i.e., Wistar sham, Wistar ECS, Gunn sham, and Gunn ECS. ECS
groups received ECS once daily for six consecutive days. Subsequently, prepulse inhibition (PPI) test was performed,
and immunohistochemistry analysis was carried out to determine the activation degree of microglia and astrocytes
in the hippocampus by using anti-CD11b and anti-glial fibrillary acidic protein (GFAP) antibody, respectively.
Results: We found PPI deficit in Gunn rats compared to Wistar rats, and it was significantly improved by ECS.
Immunohistochemistry analysis revealed that immunoreactivity of CD11b and GFAP was significantly increased in Gunn
rats compared to Wistar rats. ECS significantly attenuated the immunoreactivity of both CD11b and GFAP in Gunn rats.
Conclusions: ECS ameliorated schizophrenia-like behavior of Gunn rats and attenuated microgliosis and astrogliosis in the
hippocampus of Gunn rats. Accordingly, therapeutic effects of ECT may be exerted, at least in part, by inhibition of glial
activation. These results may provide crucial information to elucidate the role of activated glia in the pathogenesis of
schizophrenia and to determine whether future therapeutic interventions should attempt to up-regulate or down-regulate
glial functions.
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Background
Electroconvulsive therapy (ECT) has been used as a
treatment for mental disorder since the 1930s [1] because
of its effectiveness and the fast action in several psychiatric
disorders such as bipolar disorder, major depression, and
schizophrenia accompanied by catatonia, extreme depres-
sion, mania, and other affective components [2, 3]. Never-
theless, views on ECT vary; some researchers consider
that it is probably ineffective and certainly causes brain
damage, while others think it is completely safe and the
most effective treatment available in psychiatry [4]. Both
the generalized seizure and the dose of electricity used
seem to be important for the therapeutic effect of ECT,
which has multiple, varied, and lasting effects on the CNS
[5, 6]. However, the exact mechanism of therapeutic
action of ECT remains unknown.
Recent studies indicate that ECT affects the immune
system. A single ECT has been reported to up-regulate
the immune system, causing elevated levels of pro-
inflammatory cytokines [7]. On the other hand, repeated
ECT administrations appear to down-regulate the immune
system as shown by a reduction of the plasma levels of
tumor necrosis factor (TNF)-α [8]. Pro-inflammatory
cytokines, including TNF-α, are released from immune-
related glial cells in the CNS [9, 10].
A change in immune system functions associated with
glial activation may be involved in the pathogenesis of
schizophrenia [11, 12]. In fact, several postmortem brain
studies and positron emission tomography studies on
schizophrenic patients have indicated an increase in
microglial activation [13–18]. In addition, activated
astrocytes have been reported in the postmortem brains
of schizophrenia [19, 20]. Therefore, it is tempting to
determine the effect of ECT on the activation of micro-
glia and astrocytes.
It is believed that there is a relationship between
hyperbilirubinemia and schizophrenia. Schizophrenic
patients have a significantly higher frequency of hyper-
bilirubinemia relative to patients with other psychiatric
disorders and to the general healthy population [21, 22].
Gunn rats, a mutant of the Wistar strain, have a genetic
deficiency in glucuronyl transferase. This deficiency leads
to high levels of unconjugated bilirubin in their blood and
various tissue, including the brain [23, 24]. Our previous
studies have revealed that Gunn rats show a behavioral
abnormality similar to schizophrenia with deficits in
prepulse inhibition (PPI) [25, 26]. Furthermore, we
have shown that microglia are activated in the hippo-
campal dentate gyrus (DG) of Gunn rats [27, 28]. Based
on these findings, the present study evaluated the ef-
fects of electroconvulsive shock (ECS), an animal model
of ECT, on schizophrenia-like behavior, as well as on




Six-week-old male homozygous (j/j) Gunn rats and male
Wistar rats (Japan SLC, Inc., Japan) were used in this
study. The rats were housed under standard conditions
with a room temperature (RT) of 23 ± 2 °C, humidity of
55 ± 5 %, and 12-h light/12-h dark cycle (light phase
7:00 to 19:00) and with free access to food and water.
Two weeks before starting the experiment, the rats
underwent a handling procedure once daily to reduce
stress during the experiments. All procedures were per-
formed with the approval of the Shimane University
Animal Ethics Committee, under the guidelines of the
National Health and Medical Research Council of Japan.
ECS procedure
Animals were divided into four groups: Wistar sham
group (WS), Wistar ECS group (WE), Gunn sham group
(GS), and Gunn ECS group (GE) in order to get the brain
samples from sham-treated groups and from ECS-treated
groups. To avoid stress or pain induced by the ECS pro-
cedure, each rat was first anesthetized in a halothane
inhalation chamber (4 % for initial induction) with an oxy-
gen flow rate of 2–4 L/min [29]. After the rats fell asleep,
the rats were taken out from the chamber and anesthesia
was continued by putting a halothane inhalation mask
(2 % for maintenance) with an oxygen flow rate of 2–4 L/
min. In every ECS procedure, electric shock was given
under anesthesia by halothane inhalation mask.
ECS was administered transcranially via bilateral ear clip
electrodes using an E.C. Stimulator MK-810 (Muromachi
Kikai Co., Ltd., Japan). The stimulus was a sine wave
pulse, 100 v, 60 Hz, 50 mA, 1.5 s. Each stimulation re-
sulted in a typical tonic-clonic seizure lasting for less than
10 s (for review, see Additional file 1). The ECS group re-
ceived an ECS treatment once daily for 6 consecutive days.
The sham-treated control groups were handled identically
to the ECS groups including anesthesia except that no
current was delivered.
Hearing ability and PPI of startle response
A startle response measurement system (SR-Lab, San Diego
Instruments, Inc., CA) was used as described previously
[25, 28]. Each animal (n = 8 for each group) was placed
in a plexiglass cylinder where it was exposed to white
background noise at 65 dB for a 5-min acclimatization
period. This was followed by four types of trials: (1) pulse
(P) alone which consists of a 20-ms burst of white noise at
120 dB; (2) a 20-ms burst of white noise at 70 dB followed
by a 20-ms white noise at 120 dB (70 PP + P); (3) a 20-ms
burst of white noise at 80 dB followed by a 20-ms white
noise at 120 dB (80 PP + P); and (4) background noise only
(no stimulus). The interval between prepulse and pulse was
set at 100 ms. Trials were given in a pseudo-random order
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with variable intervals (5–45 s) between trials. Startle
response was measured in a session which consists of
50 trials. We identified the maximum amplitude of the
startle response (Vmax) in each trial. The mean of
Vmax was used to calculate the degree of PPI (%PPI).
The percentage of PPI was defined as the magnitude of in-
hibition due to the startle amplitude that was induced by
the prepulse. %PPI = [1 − (startle magnitude after prepulse
− pulse pair/startle magnitude after pulse only)] × 100.
In order to determine whether Gunn rats have intact
hearing, Wistar rats and Gunn rats without any treat-
ment (n = 3 for each group) were also tested with the
startle response measurement system. Each animal was
exposed to white background noise at 65 dB for a 5-min
acclimatization period. This was followed by five types
of trials: (1) pulse alone which consists of a 20-ms burst
of white noise at 85 dB; (2) pulse alone which consists of
a 20-ms burst of white noise at 90 dB; (3) pulse alone
which consists of a 20-ms burst of white noise at
100 dB; (4) pulse alone which consists of a 20-ms burst
of white noise at 110 dB; and (5) background noise only
(no stimulus). Trials were given in a pseudo-random
order with variable intervals (5–45 s) between trials.
Startle response was measured in a session which
consists of 50 trials. We measured Vmax in each trial
and compared the mean of Vmax between the Wistar
rat group and the Gunn rat group.
Immunohistochemistry
After the behavior tests, animals underwent deep intra-
peritoneal anesthesia with sodium pentobarbital (80 mg/
kg body weight) and were perfused transcardially with
500 mL of physiological saline, followed by 500 mL of
10 % formalin. The brains (n = 6 for each group) were
quickly removed and were fixed in a solution of 10 %
formalin at RT for 4 h. The brains were immersed
overnight in a cold solution of 20 % sucrose and then
were cut into 40-μm-thick serial sections using a sliding
microtome (Microm HM 430, Thermo Scientific,
Germany). Fifteen to 18 slices from each rat were
processed for each marker.
The free-floating brain sections were incubated in 1 %
H2O2 for 30 min at RT and then were pre-incubated
with 0.1 M phosphate buffer containing 3 % bovine
serum albumin, 0.4 % Triton X, and 1.5 % goat serum
for 1 h at RT. The sections were incubated for 3 days
with the rabbit anti-glial fibrillary acidic protein (GFAP)
antibody (1:2000, Abcam plc., Cambridge, UK) at 4 °C.
Similar procedures were done with the mouse anti-
CD11b antibody (1:500, Abcam plc., Cambridge, UK)
except that 1.5 % horse serum was used instead of goat
serum. Subsequently, the sections were incubated for
1 h with biotinylated anti-rabbit (or anti-mouse) IgG
antibody (1:200, standard ABC kit, Vector lab, Inc., CA)
at RT. For diaminobenzidine (DAB) staining, the sections
were incubated for 1 h at RT in PBS containing the
avidin-biotin peroxidase complex solution. The immuno-
reactivity in the sections was developed by incubating in
PBS containing 0.5 % DAB and 0.1 % H2O2 for 10 min.
The DAB reaction was halted by PBS. The sections were
mounted onto gelatin-coated slides and were sunk in
graded alcohol baths for dehydration.
For immunofluorescent staining, the sections were
incubated with the rabbit anti-GFAP antibody (1:500)
followed by incubation with Cy3 conjugated anti-rabbit
IgG antibody (1:1000, Jackson ImmunoResearch, PA) and
4',6-Diamidino-2-Phenylindole (DAPI) (0.5 μg/mL,
Sigma-Aldrich, MO) for 3 h at RT. The sections incu-
bated with mouse anti-CD11b antibody (1:500) were incu-
bated in Alexa Fluor 488 conjugated anti-mouse IgG
antibody (1:500, Life Technologies Eugene, OR) and
DAPI (0.5 μg/mL) for 3 h at RT.
Image analysis
The intensity of astroglial and microglial immunoreactivity
in the DAB staining was measured by a computer-assisted
image analysis program (Image J 1.47v, Wayne Rasband,
National Institutes of Health, MD). GFAP- or CD11b-
labeled glial cells were examined under a light microscope
(Nikon, Eclipse Cί, Japan) with a 20× objective lens.
Images were captured from three areas within the hippo-
campus, namely the dentate gyrus (DG), the cornu ammo-
nis (CA)1, and the CA3. Twenty images were captured
bilaterally with a digital Nikon 1 J1 camera from each area
(10 images from the left hemisphere and 10 images from
the right hemisphere). Overall, 60 images per animal were
analyzed. The software automatically converted all immu-
nolabeled element beyond the threshold range into pure
black pixels and converted the rest of the image into pure
white pixels (Fig. 1). The software then calculated the per-
centage of pure black pixels for statistical analysis.
Statistical analysis
All the data are presented as the mean ± standard error
of the mean (S.E.M.). Differences among the groups
were evaluated by using one-way ANOVA followed by
the post hoc Fisher’s least significant different test. This
analysis was performed with SPSS software (Dr. SPSS II
for Windows v.11.0.1J, SPSS Japan Inc., Japan). A p value
less than 0.05 was considered statistically significant.
Results
Effect of ECS on PPI deficits in Gunn rats
The PPI test was performed with two different prepulse
stimulus intensities, namely 70 and 80 dB. At 70-dB
prepulse stimulus intensity, %PPI was 40.94 ± 7.12 in the
WS group, 43.81 ± 4.99 in the WE group, 19.32 ± 5.30 in
the GS group, and 36.18 ± 7.72 in the GE group. As
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shown in Fig. 2a, %PPI at 70 dB was significantly
decreased in the GS group compared to the WS group
(p = 0.024). After consecutive administration of ECS for
6 days, we found a higher %PPI at 70 dB in the GE
group compared to the GS group, although the ECS
efficacy did not reach significance.
At 80-dB prepulse stimulus intensity, %PPI was
76.40 ± 2.17 in the WS group, 72.70 ± 4.45 in the WE
group, 46.93 ± 4.67 in the GS group, and 68.87 ± 4.95
in the GE group. As shown in Fig. 2b, %PPI at 80 dB
was significantly lower in the GS than the WS group
(p < 0.001). After the ECS administration, at 80 dB, %PPI
in the GE group was significantly increased compared to
the GS group (p = 0.001), suggesting that ECS improved
the schizophrenia-like behavior of Gunn rats. There was
no significant difference between the WS group and the
WE group both at 70 and at 80 dB.
It is well known that both young [30] and adult [31]
Gunn rats have changes in the brainstem auditory sys-




Fig. 1 Representative images of DAB staining and of black-/white-pixel conversion in the DG area (a), the CA1 area (b), and the CA3 area (c)
Fig. 2 Effect of ECS on prepulse inhibition at 70 dB (a) and 80 dB (b). Each value is the mean ± S.E.M. (n = 8 per group). *p < 0.05, **p < 0.001
compared to the Wistar sham group. #p < 0.005, compared to the Gunn sham group
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homozygous jaundiced Gunn rats have small but statisti-
cally significant abnormalities in the auditory system
using brainstem auditory evoke potentials (BAEPs). On
the other hand, Levi et al. [32] have shown that all
homozygous jaundiced Gunn rats have preserved hear-
ing ability in auditory nerve and brain stem responses,
also known as BAEPs. Since studies of BAEPs in Gunn
rats have found normal and abnormal auditory function,
we determined whether Gunn rats have an intact hear-
ing in our experimental system. We measured startle
amplitude both in Wistar and Gunn rats (n = 3) by using






























Fig. 3 Startle amplitude of the Wistar group compared to the Gunn group at the noise level 85, 90, 100, and 110 dB. Each value is the mean ± S.E.M.
(n = 3 per group). NS not significant
Fig. 4 Representative immunofluorescent images of CD11b combined with DAPI in the DG area of the Wistar sham group (a), the Wistar ECS
group (b), the Gunn sham group (c), and the Gunn ECS group (d). The scale bar indicates 100 μm
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and 110 dB (with 20-ms duration, white noise). As
shown in Fig. 3, the startle response increased with in-
creasing volume and reached a maximum at 110 dB
both in Gunn and Wistar rats. At each noise level, there
was no significant difference in startle response between
Gunn and Wistar rats. Based on this result, we consider
that Gunn rats show intact hearing in our experimental
system using the PPI test instrument.
Effect of ECS on microglial activation in Gunn rats
We evaluated the CD11b immunoreactivity in the DG,
CA1, and CA3 regions of the hippocampus. In the DG,
immunofluorescent images showed a high expression of
CD11b in the GS group (Fig. 4c) compared to the WS
group (Fig. 4a). The high expression of CD11b was
considerably reduced, and the cell body of each
microglia looks shrunk after ECS (Fig. 4d). Quantifi-
cation of data for CD11b showed that CD11b immu-
noreactivity was significantly higher in the GS group
compared to the WS group in the DG (p = 0.002)
(Fig. 6a). After ECS, the CD11b immunoreactivity in
the GE group was significantly decreased compared
to the GS group (p = 0.038) (Fig. 6a).
In the CA1, immunofluorescent images showed a high
expression of CD11b in the GS group (Fig. 5c) compared to
the WS group (Fig. 5a). ECS administration conferred the
tendency to reduce the high expression of CD11b (Fig. 5d).
Quantification of data for CD11b showed that CD11b
immunoreactivity was also significantly higher in the GS
group than the WS group in the CA1 (p < 0.001) (Fig. 6b)
and in the CA3 (p < 0.001) (Fig. 6c). ECS administration
showed a tendency to reduce the CD11b immunoreactivity,
but it did not reach significance in these regions (Fig. 6b, c).
No significant difference was observed between the WS
group and the WE group in all three regions of the
hippocampus.
Effect of ECS on astrocytic activation in Gunn rats
We also examined the immunoreactivity of GFAP in
the hippocampal DG, CA1, and CA3. Figure 7c rep-
resents immunofluorescent analysis and shows high
expression of GFAP in the DG of the GS group
compared to the WS group (Fig. 7a). ECS adminis-
tration considerably decreased the GFAP immunore-
activity in the GE group (Fig. 7d). Quantitation of
GFAP immunoreactivity in the DG showed that the
Fig. 5 Representative immunofluorescent images of CD11b combined with DAPI in the CA1 of the Wistar sham group (a), the Wistar ECS group
(b), the Gunn sham group (c), and the Gunn ECS group (d). The scale bar indicates 100 μm
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GFAP expression in the GS group was significantly
higher than in the WS group (p = 0.008) (Fig. 9a).
The ECS administration significantly suppressed the
increased GFAP immunoreactivity in the DG of
Gunn rats (p = 0.004) (Fig. 9a).
Figure 8c is a representative immunofluorescent image
which shows increased immunoreactivity of GFAP in the
CA1 region of the GS group compared to the WS group
(Fig. 8a). Such increased expression of GFAP was
considerably reduced after ECS (Fig. 8d). Quantification
of data for GFAP showed that the GFAP immunoreactiv-
ity in the CA1 was significantly higher in the GS group
than in the WS group (p = 0.002) (Fig. 9b). The ECS ad-
ministration significantly reduced the increased GFAP
immunoreactivity in the CA1 of Gunn rats (p = 0.022)
(Fig. 9b).
In the CA3 region, there was no significant difference
between any two groups (Fig. 9c). There was no significant
difference of the GFAP immunoreactivity between the WS
group and the WE group in all the three regions.
Discussion
There were three major findings in the present study.
First, ECS administration significantly ameliorated the
schizophrenia-like behavior in Gunn rats. Second, ECS
inhibited microglial activation in the hippocampi of
Gunn rats, as shown by the decreased immunoreactivity
of CD11b. Third, ECS also attenuated astrocytic activa-
tion in the hippocampi of Gunn rats, as indicated by the
reduced expression of GFAP. There have been several
animal studies which evaluated the effects of ECS on
glial cells in the normal brain [33–40]. However, to our
knowledge, there have been only a few studies which ex-
amined the effects of ECS on glial cells in the patho-
logical brain [41, 42]. The present study determined the
effect of ECS on the microglial activation and astrocytic
activation in the diseased brain by using Gunn rats.
Braff et al. [43–45] have shown that schizophrenic pa-
tients exhibited significant PPI deficits compared to
normal participants. Moreover, numerous studies have
confirmed the PPI deficiency in schizophrenic patients
Fig. 6 Effect of ECS on microglial activation. Mean percentage of pure black pixel indicating CD11b immunoreactivity in the DG area (a), the CA1
area (b), and the CA3 area (c). Each value is the mean ± S.E.M. (n = 6 per group). *p < 0.001, **p < 0.005, compared to the Wistar sham group.
#p < 0.05, compared to the Gunn sham group. DG dentate gyrus, CA cornu ammonis
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[46–48] and that antipsychotic drugs can not only ameli-
orate symptoms of schizophrenia but also improve the
PPI deficit [49, 50]. Our previous studies have demon-
strated that Gunn rats exhibit a schizophrenia-like behav-
ior which consists of impaired sensorimotor gating as
shown by decreased %PPI compared to Wistar rats, a
normal rat strain [25, 26, 28]. Accordingly, Gunn rats
showing such a schizophrenia-like behavior seems to be
an appropriate animal model to investigate the therapeutic
mechanism of ECS, the animal counterpart of ECT.
Continuous or maintenance ECT treatments have
been reported to be effective as a relapse prevention
treatment. Indications for maintenance ECT treatment
include patients with rapid relapse after initial ECT,
severe symptoms, psychotic symptoms, and the inabil-
ity to tolerate medications [4, 51]. In a chart review
by Kristensen, 18 patients received maintenance ECT
in addition to antipsychotics. It was very effective in
stabilizing the patients and reducing the length of
hospital stay [52]. Another study has shown that con-
tinuous or maintenance ECT is safe and effective for
chronically hospitalized patients. It improves general
functioning and reduces verbal aggression and self-
harm [53]. In the present study, consecutive adminis-
tration of ECS for 6 days significantly ameliorated the
impaired sensorimotor gating in Gunn rats as demon-
strated by the increased percentage of PPI. Consistent
with our finding, Chao et al. [54] have clarified that re-
peated ECS improves the PPI disruption caused by
chronic administration of methamphetamine.
In schizophrenic patients, the disability to focus on
what is important (i.e., attentional deficit) can be
reflected by deficient attentional modulation of PPI
[46, 55]. As attentional deficit is one of the core
symptoms in attention-deficit/hyperactivity disorder
(ADHD), the PPI test might be used as a test for
ADHD. Schulz-Juergensen et al. [56] showed that the
median baseline PPI of ADHD patients was below the
value of age-matched normal controls and that me-
thylphenidate significantly improved this deficiency.
Although both schizophrenic patients and ADHD pa-
tients exhibit efficient attentional modulation of PPI,
their attentional deficits are fundamentally different in
some perspectives [57].
In this study, the hippocampus was intensively ana-
lyzed as the region of interest, since the hippocampus
Fig. 7 Representative immunofluorescent images of GFAP combined with DAPI in the DG of the Wistar sham group (a), the Wistar ECS group (b),
the Gunn sham group (c), and the Gunn ECS group (d). The scale bar indicates 100 μm
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has been suggested to regulate PPI [58–60]. Further-
more, increasing evidence implies that the hippocampus is
involved in the pathophysiology of schizophrenia [61–63]
and is particularly vulnerable to inflammatory insults due
to its high density of receptors for inflammatory mediators
[64, 65].
The present study showed that CD11b expression was
significantly increased in the hippocampal DG, CA1, and
CA3 areas in Gunn rats compared to Wistar rats. The
finding that microglia in the hippocampus of Gunn rats
are activated is in line with our previous studies [28, 66].
Gunn rats have high levels of unconjugated bilirubin
(UCB) in their blood [23]. Although UCB entrance into
the brain is prevented by the blood-brain barrier (BBB),
the free fraction of UCB still diffuses into the brain
through the BBB [67–69] and causes glial activation
[70, 71]. After ECS, we found a significant decrease in
CD11b expression in the DG, but not in the CA1 and
CA3. Our previous study using Gunn rats also showed
that minocycline attenuated microglial activation in the
hippocampal DG and thus improved the schizophrenia-
like behavior [28]. Based on these findings, abnormal
behavior similar to schizophrenia may be associated
with microglial activation in the DG. Furthermore, ECS
may inhibit microglial activation in the pathological
brain, and this inhibitory effect on activated microglia
may be a part of the therapeutic action of ECS.
Not only microglia, but astrocytes are also activated by
UCB [72]. Astrocytes, like microglia, are activated in a re-
sponse to injury or other pathological processes in the
CNS and have either a neuroprotective or a neurotoxic
role [73, 74]. In the present study, the level of GFAP ex-
pression in the hippocampi of Gunn rats was significantly
increased compared to Wistar rats in the DG and CA1.
After the ECS administrations, the GFAP expression was
significantly decreased in the DG and CA1. The abnormal
behavior in Gunn rats may be caused by high levels of
UCB which may precede chronic inflammation and
neurodegeneration in the Gunn rat brain. Therefore, it is
presumed that activated astrocytes may play a neurotoxic
role in Gunn rats and that ECS may exert therapeutic
effect through inhibition of such activation of astrocytes.
Our previous study has indicated that Gunn rats show
the increased number of apoptotic cells and reduced
neurogenesis in the subgranular zone of their hippo-
campi [25]. Zarubenko et al. [75] have shown that
Fig. 8 Representative immunofluorescent images of GFAP combined with DAPI in the CA1 of the Wistar sham group (a), the Wistar ECS group
(b), the Gunn sham group (c), and the Gunn ECS group (d). The scale bar indicates 100 μm
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repeated ECS causes neuronal death. On the other hand,
a number of studies have shown that repeated ECS
increases neurogenesis [76–78]. Moreover, Conti et al.
[79] have demonstrated that nerve growth factor in the
hippocampus was up-regulated after chronic ECS. Based
on these findings, we presume that ECS may cause neur-
onal cell death, while ECS also induces neurogenesis to
replace the death neuron. Not only neurogenesis, studies
on the normal rodent brain have also shown that ECS
increases angiogenesis [80, 81]. Accordingly, ECS may
also induce neurogenesis and angiogenesis even in the
pathological hippocampi of Gunn rats. The inhibitory ef-
fects of ECS on activated microglia and activated astro-
cytes seem to lead to the reduction of inflammatory
activities in the pathological hippocampus. Thus, the
ECS-induced generation of new neurons may replace
the neurons damaged by the high levels of UCB, while
the angiogenesis may repair the BBB and prevent the
brain from excessive entrance of UCB. All these things
induced by ECS appear to work together to improve the
schizophrenia-like behavior in Gunn rats.
Our results showed that ECS significantly suppressed
the CD11b expression only in the DG, not in the CA1
and CA3. A study on additional genes excitatory amino
acid transporter-1 (EAAC1), that are known to be in-
volved in neuroprotection, has shown that EAAC1 was
significantly up-regulated in the DG following chronic
ECS, while no changes were detected in other hippo-
campal subregions, including CA1 and CA3 [82]. It has
been demonstrated that repeated ECS significantly in-
creases the synaptic response in the DG only [83]. In
addition, the significant inhibitory effect of ECS on the
GFAP expression has been observed in the DG and
CA1, but not in the CA3. Consistent with our finding,
Conti et al. [79] have demonstrated that nerve growth
factor in the hippocampus was up-regulated after
chronic ECS in the DG and the CA1, but not in the
CA3. Moreover, allopregnanolone infused into the CA1
of the hippocampus has been shown to enhance the PPI
of startle response in Wistar rats [58]. Based on these
findings, it is tempting to presume that the response to
ECS treatment is regionally selective and the mechanism
of ECS to improve PPI deficit may be related to the DG
and CA1 rather than the CA3.
Mononuclear phagocytic cells may play a key role in
the pathogenesis of major psychiatric disorders. In fact,
a study by Rothermundt reported a slight increase in the
mean absolute and relative monocyte counts of the
schizophrenic patients [84]. Other studies also showed a
monocytosis and a high number of CD14+ cells in un-
treated schizophrenia patients [85, 86]. Furthermore, in
the cerebrospinal fluid of schizophrenic patients, there
was an accumulation of monocytes and macrophages
during acute psychotic episodes [87].
Fig. 9 Effect of ECS on astrocytic activation. Mean percentage of pure black pixel indicating GFAP immunoreactivity in the DG area (a),
the CA1 area (b), and the CA3 area (c). Each value is the mean ± S.E.M. (n = 6 per group). *p < 0.005, **p < 0.01, compared to the Wistar
sham group. #p < 0.05, ##p < 0.005, compared to the Gunn sham group
Limoa et al. Journal of Neuroinflammation  (2016) 13:230 Page 10 of 13
Our finding that ECS treatment inhibits activated glial
cells in Gunn rats is inconsistent with an ECS study on
normal rats by Jansson who demonstrated that ECS
administration causes glial activation in several limbic
regions, characterized by morphological changes and by
the appearance of subpopulations of microglia and as-
trocytes [36]. Indeed, the majority of ECS studies on
normal animals has shown that ECS has no effect on
the activation/proliferation of microglia and astrocytes
[34, 35] or even increases the glial activation/prolifera-
tion [38, 39]. Only one study has reported that ECS re-
duces the density of microglial process in the murine
hippocampus [37] and one other has shown that ECS
inhibits GFAP expression in the rat hippocampus [33].
Therefore, the effect of ECS on glial activation in the
pathological brain may be different from that in the
normal brain, and further studies on this issue are
clearly warranted.
Conclusions
In conclusion, our findings indicate that ECS on Gunn
rats ameliorates schizophrenia-like behavior and attenu-
ates microgliosis in the DG and astrogliosis in the DG
and the CA1 of Gunn rats. Accordingly, therapeutic
mechanism of ECT may be exerted in part by inhibition
of glial activation. These results may also provide crucial
information to elucidate the role of activated glia in the
pathogenesis of schizophrenia and to determine whether
future therapeutic interventions should attempt to up-
regulate or down-regulate glial functions.
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